• About us
• Contact

Advertisement

Organisation › Details

ICR Consilium Strategic Communications

Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects. *

 

	Start	2023-09-12 renamed
	Group	ICR (Group)
	Predecessor	Consilium Strategic Communications Ltd. (CSC)
	Industry	public relations / investor relations / marcom (services)
	Industry 2	healthcare
	Person	Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)
	Person 2	Fennell, Amber (Bielecka, Amber) (Consilium Strategic Communications 201307– Co-founder)
	Region	London, Greater London
	Country	United Kingdom (GB)
	City	EC2R 7HG London
		Address record changed: 2023-11-17
Basic data	Employees	n. a.
		* Document for »About Section«: Consilium Strategic Communications Ltd.. (10/15/20). "Press Release: Consilium Strategic Communications Advises Compass Pathways on Its Successful Initial Public Offering". London.
		Record changed: 2023-11-17

Advertisement

More documents for ICR (Group)

• [1] ICR Inc.. (9/12/23). "Press Release: ICR Acquires Consilium Strategic Communications, Creating Global Leader in Healthcare Communications and Investor Relations". New York, NY....
• [2] Consilium Strategic Communications Ltd.. (2/20/23). "Press Release: Consilium Strategic Communications Expands International Presence in US and Europe with Two Senior Strategic Advisor Appointments". London....
• [3] Consilium Strategic Communications Ltd.. (5/6/22). "Press Release: Consilium Strategic Communications Appoints Tracy Cheung as Partner". London....
• [4] OMass Therapeutics Ltd.. (4/28/22). "Press Release: OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases". Oxford....
• [5] Emergex Vaccines Holding Ltd.. (11/18/20). "Press Release: Emergex Vaccines Raises US$11 Million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases". Abingdon....
• [6] Consilium Strategic Communications Ltd.. (11/10/20). "Press Release: Consilium Strategic Communications Strengthens Global Team in the US and Europe". London....
• [7] Consilium Strategic Communications Ltd.. (10/15/20). "Press Release: Consilium Strategic Communications Advises Compass Pathways on Its Successful Initial Public Offering". London....
• [8] Oasmia Pharmaceutical AB. (8/10/20). "Press Release: Oasmia Pharmaceutical Appoints Peter Selin as Chief Business Officer". Uppsala....
• [9] Consilium Strategic Communications Ltd.. (9/26/19). "Press Release: Consilium Strategic Communications Expands International Senior Team with Four New Appointments". London & Boston, MA....
• [10] Consilium Strategic Communications Ltd.. (7/10/19). "Press Release: Consilium Strategic Communications Sponsors Future of Healthcare Investor Forum 2019 at London Stock Exchange". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.